Poster Session III

Patrick M. Callahan,Shaojie Wang,Walter Xie,Sofya Dragan,Shanzhong Sun,T. Michael,B. Tanowitz Herbert,Wayne Rowe,Ashok Tehim,David Lowe,James R. Barrett,Pierre N. Tariot,Peter M. Aupperle,Beth Safirstein,Stephen Graham,Grace M. Lee,Michael Tocco,Steven T. DeKosky,Chester A. Mathis,Julie C. Price,Brian J. Lopresti,Carolyn C. Meltzer,Scott K. Ziolko,Jessica A. Hoge,Nicholas D. Tsopelas,William E. Klunk,George E. Bigelow,Kenzie L. Preston,John Schmittner,Charles P. O’Brien,Qunming Dong,David R. Gastfriend,Mohammed Shoaib,Mona Boules,Iver H. Iversen,Alfredo Oliveros,Amanda M. Shaw,Katrina Williams,Yuanyuan Liang,Paul Fredrickson,Elliott Richelson,Rupa Gopalan,Chi‐Hyung Ahn,Paolo Mannelli,Ashwin A. Patkar,Dan Weese,Tong Lee,Everett H. Ellinwood

DOI: https://doi.org/10.1038/sj.npp.1301268

2006-01-01

Neuropsychopharmacology

Abstract:Background: Alpha7 nicotinic acetylcholine receptors (nAchRs) play a vital role in cognition and alpha7 nAchR agonists represent a novel drug class with therapeutic potential to restore cognitive abnormalities associated with Alzheimer's disease, schizophrenia and other CNS disorders.MEM 3454 is a novel alpha7 nAchR partial agonist with 5HT3 receptor antagonist activity.Here we describe the preclinical pharmacological and behavioral effects of MEM 3454 as well as the Cognitive Drug Research (CDR) battery test results obtained from healthy volunteers during the Phase1 clinical trial.Methods: MEM 3454 was characterized using preclinical pharmacological and behavioral assays.In the Phase1 clinical trial, MEM 3454 was evaluated using the Cognitive Drug Research (CDR) battery test in a double-blind placebo-controlled study in healthy volunteers.Results: In a proprietary human recombinant mutant alpha7 nAchR cell line, MEM 3454 activated alpha7 nAchRs and produced concentration-dependent increases in calcium flux signals that were rightshifted by the alpha7 nAchR antagonist methyllycaconitine (MLA).In a monkey wild-type alpha7 nAchRs cell line, MEM 3454 elicited an EC50 of 0.4 µM and a maximum response of 67% compared to that of acetylcholine, demonstrating a partial agonist profile.MEM 3454 displayed high affinity at rat alpha7 nAchRs (Ki= 6 nM; [ 3 H]MLA-labeled sites) and human 5-HT3 receptors (Ki= 2 nM; [ 3 H]BRL43694labeled sites).MEM 3454 showed minimal affinities/efficacies at other nAchRs (α4β2, α3β, and α1β1δγ) and maintained selectivity in broad receptor and enzyme profiling.MEM 3454 (0.01-10 mg/kg, ip, sc or po) was assessed in several preclinical behavioral models representing multiple cognitive (e.g., attentional, episodic, spatial reference and working memories) and sensory gating domains.MEM 3454 enhanced object recognition memory at a 48hr delay internal, an effect antagonized by MLA and pharmacological tolerance did not occur after 10 days of repeated administration.MEM 3454 completely reversed the water-maze spatial memory performance deficits in aged cognitively-impaired rats and reversed the DMTS performance deficits in aged rhesus monkeys.MEM 3454 produced significant improvements in sustained visual attention (i.e., percent correct hit accuracy performance) via the signal detection task and completely reversed the PCP-induced attentional set-shifting extradimensional discrimination performance deficit.MEM 3454 also significantly reversed the apomorphine-induced prepulse startle inhibition (PPI) deficit.In Phase1 clinical testing in healthy subjects, Cognitive Drug Research (CDR) battery test performance was significantly improved particularly in domains associated with secondary memory.Furthermore, pharmacokinetic parameters from these studies reveal linear, dose-dependent increases in exposures in single and repeated dose studies.Discussion: The preclinical data presented here, along with preliminary findings in healthy human subjects, suggests that MEM 3454 represents a new and promising therapeutic candidate for the treatment of cognitive symptoms associated with Alzheimer's disease, schizophrenia and other CNS disorders.